COAG
Hemab Therapeutics Holdings, Inc.Company Information
- Company Name
- Hemab Therapeutics Holdings, Inc.
- CIK
- CIK0002114044
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- COAG: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- COAG
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-16
- Last sale
- —
- Shares purchased (TTM)
- 176,793
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 35,528,302
- Shares outstanding
- 30,111,338
- Ownership
- 117.99%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -14.17%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||
| Cash And Cash Equivalents At Carrying Value | 237 | 50 | ||||||
| Marketable Securities Current | 220 | 114 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 6 | ||||||
| Assets Current | 464 | 169 | ||||||
| Property Plant And Equipment Net | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | ||||||
| Other Assets Noncurrent | 2 | 4 | ||||||
| Assets | 468 | 175 | ||||||
Liabilities Current | ||||||||
| Accounts Payable Current | 6 | 6 | ||||||
| Accrued Liabilities Current | 6 | 7 | ||||||
| Operating Lease Liability Current | 0 | 1 | ||||||
| Liabilities Current | 13 | 13 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | ||||||
| Liabilities | 14 | 14 | ||||||
Stockholders Equity | ||||||||
| Additional Paid In Capital | 686 | 6 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -229 | -205 | ||||||
| Stockholders Equity | 454 | -199 | ||||||
| Liabilities And Stockholders Equity | 468 | 175 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 5 | 1 | ||||||
| Preferred Stock Shares Issued | 0 | 1 | ||||||
| Preferred Stock Liquidation Preference Value | - | 349 | ||||||
| Preferred Stock Shares Outstanding | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialHemab Therapeutics Holdings, Inc. (COAG) — SEC Financial Statements & Analysis
Hemab Therapeutics Holdings, Inc. (COAG) is a biological products, (no diagnostic substances) company, incorporated in DE. Hemab Therapeutics Holdings, Inc. trades on Nasdaq as: COAG. Hemab Therapeutics Holdings, Inc. (COAG)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Hemab Therapeutics Holdings, Inc. carries a market cap of $1.11B, a P/B ratio of -2.43x, and an enterprise value of $868.62M. On the balance sheet, it maintains a current ratio of 35.85x, a quick ratio of 35.34x, working capital of $451.05M, a debt-to-equity ratio of -0.03x, a debt ratio of 0.03, and net debt of $-237.37M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.11B
- P/B TTM
- -2.43x
- Debt To Equity
- -0.03x
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Hemab Therapeutics Holdings, Inc. in?
Hemab Therapeutics Holdings, Inc. (COAG) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does COAG trade on?
Hemab Therapeutics Holdings, Inc. (COAG) trades on the Nasdaq.
Where is Hemab Therapeutics Holdings, Inc. incorporated?
Hemab Therapeutics Holdings, Inc. is incorporated in DE.
When was Hemab Therapeutics Holdings, Inc. (COAG)'s most recent SEC filing?
Hemab Therapeutics Holdings, Inc. (COAG)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is COAG's market cap?
Hemab Therapeutics Holdings, Inc. (COAG) has a market capitalization of $1.11B as of 2026-06-30.